Episodes

  • BrainCheck as a Digital Cognitive Assessment Tool

    BrainCheck as a Digital Cognitive Assessment Tool
    Nov 8 2024
    Kim Rodriguez, CEO of BrainCheck, provides an overview of the company's cognitive assessment plan and how clinicians can use these tools in practice. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Show More Show Less
    7 mins
  • Kramer, Van Dyck

    Kramer, Van Dyck
    Sep 27 2024
    Lynn D. Kramer, MD, FAAN, Chief Clinical Officer, Deep Human Biology Learning at Eisai and a member of the Eisai Executive Committee, and Christopher van Dyck, MD, Professor of Psychiatry, Neurology, and Neuroscience, Yale School of Medicine, provide an overview of key results from the Clarity AD clinical trial assessing the safety and efficacy of lecanemab in people with early Alzheimer disease presented at the 2024 Alzheimer's Association International Conference. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Show More Show Less
    12 mins
  • CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 3

    CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 3
    Sep 21 2024
    In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this episode, Dr. Schindler provides advice for physicians about communicating biomarker test results with their patients. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Show More Show Less
    10 mins
  • CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 2

    CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 2
    Sep 21 2024
    In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this episode, Dr. Schindler presents an overview of factors influencing the selection of cerebrospinal fluid, PET, and blood-based biomarker tests. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Show More Show Less
    17 mins
  • CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 1

    CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 1
    Sep 21 2024
    In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this episode, Dr. Schindler discusses key factors physicians should consider when ordering a biomarker test and recommendations for how physicians should communicate the need for a particular test with their patients. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Show More Show Less
    9 mins
  • Labcorp's Biomarker Testing for Alzheimer Disease

    Labcorp's Biomarker Testing for Alzheimer Disease
    Sep 16 2024
    Joseph M. Volpe, MD, Discipline Director, Clinical Neuroscience, Labcorp, discusses biomarker testing for Alzheimer disease and dementia,, including current offerings, reimbursement, and future directions in this evolving area. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Show More Show Less
    13 mins
  • What Neurologists Should Know About End-of-Life Care Discussions

    What Neurologists Should Know About End-of-Life Care Discussions
    Jul 19 2024
    Dan Morhaim, MD, board-certified emergency medicine and internal medicine physician, and former 24-year Maryland State Legislator, highlights the importance of discussing end-of-life care issues with dementia patients and best practices for physicians to follow when broaching this topic. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Show More Show Less
    21 mins
  • Insights into the Role of Tau in Alzheimer Disease and Neurodegenerative Disorders

    Insights into the Role of Tau in Alzheimer Disease and Neurodegenerative Disorders
    Jul 15 2024
    Virginia Man-Yee Lee, PhD, who serves as the John H. Ware 3rd Endowed Professor in Alzheimer's Research at the University of Pennsylvania Perelman School of Medicine, the Director of the Center for Neurodegenerative Disease Research, and Co-Director of the Marian S. Ware Center for Alzheimer's Drug Discovery, presents an overview of tau biomarker testing and research. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Show More Show Less
    22 mins